Recent Articles from GlobeNewswire

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’ equity of $2.5M.

Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies 

SAN JOSE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the cybersecurity platform for the AI era, will release fourth quarter fiscal year 2026 earnings after the market closes on Thursday, September 3, 2026. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.

SIMON’S TOWN, South Africa, Aug. 06, 2026 (GLOBE NEWSWIRE) -- National Women’s Month in August will see South Africa’s 18-year-old Amber-Rose Berry of Cape Town attempt to become the youngest South African woman to swim the English Channel, according to the Channel Swimming Association. The CMO Council, a supporting partner of this initiative, invites brands, companies and coalitions to get behind Amber-Rose Berry and build momentum for her big swim and the cause she supports.

Company combines 35 years of experience, operations in more than 20 countries, and a growing North American presence to help organizations turn AI and technology investments into measurable business outcomes

TEJON RANCH, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tejon Ranch Co. (NYSE:TRC), ("Tejon" or the "Company"), a diversified real estate, land and agribusiness company, today announced financial results for the second quarter ended June 30, 2026.

Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the progression of the Company’s clinical development program.

GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.

-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 --

SAN MATEO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Freshworks Inc. (NASDAQ: FRSH) today announced that Tyler Sloat, Chief Operating Officer and Chief Financial Officer, is scheduled to participate in a fireside chat at the Oppenheimer 29th Annual Technology, Internet & Communications Conference on Wednesday, August 12, 2026 at 9:25 a.m. Pacific Time (12:25 p.m. Eastern Time).         

Enterprises shift AI spending toward runtime control fueling 25% growth; OutSystems veteran joins to scale go-to-market

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Rezolve Ai (NASDAQ: RZLV), a global leader in agentic commerce and AI-powered customer engagement, today announced that it will release its financial results for the six months ended June 30, 2026, on Tuesday, September 1, 2026.

ROCKVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- X-Energy, Inc. (Nasdaq: XE) (“X-energy” or “the Company”), a leading developer of advanced nuclear reactors and fuel technology, and Centrus Energy Corp. (NYSE: LEU) (“Centrus”), a trusted supplier of nuclear fuel, services and technology, today announced a definitive agreement for Centrus to provide X-energy with enrichment services for Low-Enriched Uranium (“LEU”) and High-Assay Low-Enriched Uranium (“HALEU”). At full execution, the agreement meaningfully de-risks X-energy's Xe-100 project pipeline and would secure HALEU to support a portion of the initial fuel needs of X-energy’s 11.5 GW commercial pipeline.

Six new clients, including a multistate operator, validate demand for retirement infrastructure built specifically for the cannabis workforce

PALO ALTO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence (AI) is rapidly moving from pilot projects to real-world deployment across the energy sector, there is a growing need for trusted, consistent methods to evaluate operational risk. EPRI today announced SAFERai.power, a collaborative initiative that will equip utilities and technology providers with the tools, evidence, and guardrails needed to scale AI responsibly.

VANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO; OTCQB: ORRCF) ("Oroco" or the "Company") is pleased to report the third set of assay results from its Phase 2 resource drilling program focused on the South Zone at its Santo Tomás copper project, Choix, Sinaloa, Mexico. Results are reported for drill holes S027 and S030 through S034.   The Company continues drilling with three rigs on site.

Second quarter 2026 GAAP net income of $3.1 million or $0.23 per basic weighted average common share and Distributable Earnings(1) of $3.9 million or $0.29 per basic weighted average common share

– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook –

Jena, Germany, Aug. 06, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced financial results for the three months ended June 30, 2026, and provided a business update.

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 

Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count

CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update. Abeona will announce its financial results for this period in a press release to be issued prior to the call.

Issues FY27 guidance and raises adjusted segment operating margin target by 300 bps to 30% by FY31

Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027

UNESCO platform expands global access to the LSLRCC supporting climate-adaptive drinking water infrastructure planning

LOWELL, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal third quarter ended July 3, 2026.

MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the 46th Annual Canaccord Genuity Growth Conference on Tuesday, August 11, 2026 at 1:30 p.m. ET in the United States.

Notebook PCs’ share of total U.S. tech revenue projected to reach a five-year high in 2026.

Cloud subscriptions revenue increased 23% year-over-year to $131.7 million

Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year

Conference Call and Webcast Today at 8:30 a.m. ET

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses.

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved therapy

U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year

New Prime Contractor Relationship Expands Safe Pro’s Growing Network of Leading Defense Sector Relationships

Total ARR of $360.5 Million, an Increase of 2% Versus Prior Year. GAAP Net Income of $1.1 Million Versus Net Loss in Prior Year Period. Operating Cash Flow of $5.1 Million

 Total Revenue of $222.8 million;Service Revenue of $191.3 million, up 2% sequentially

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026

Second quarter revenue grew 36% year-over-year to $1.12 billion

BASEL, Switzerland and LONDON and NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2026, and provided a business update.

- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027

Operational Highlights for the Second Quarter of 2026

New Low-Dose, Sessionable THC Beverage Format Reinforces Tilray’s Leadership in Canada’s Cannabis Beverage Category

PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026

CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026.

DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Priovant today announced that the first patients have been enrolled in the Phase 3 study evaluating brepocitinib in cutaneous sarcoidosis (CS). This follows brepocitinib’s Phase 2 study, the first positive placebo-controlled study in CS, which led to FDA Breakthrough Therapy Designation.

Novo co-founder Tyler McIntyre joins as Head of Banking; OpenFX will be launching a waitlist for their multi-currency accounts product, the first one hundred companies to join the waitlist receive $30,000 in fee credits

SANTA MONICA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) (“Macerich”) announced today that its operating partnership, The Macerich Partnership, L.P. (“Macerich Partnership”), intends to offer, subject to market and other conditions, $600 million aggregate principal amount of exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Macerich will fully and unconditionally guarantee the notes on a senior, unsecured basis. Macerich Partnership also expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $90 million aggregate principal amount of notes.

Delivered Year-over-Year Revenue Growth in Q4 and Exceeded Full Year FY26 Free Cash Flow Target

GAAP revenue decreased 3% year to date and 4% in the quarter;GAAP EPS decreased 33% year to date and 37% in the quarter;Adjusted revenue decreased 3% year to date and 4% in the quarter;Adjusted EPS decreased 21% year to date and 26% in the quarter;Company updates 2026 organic revenue and adjusted EPS outlook

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026

DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a business update.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (NYSE: RHLD), an operating management company responsible for providing management services to the operating businesses of GPGI, Inc. (“GPGI”) (NYSE: GPGI), today reported financial results for its fiscal second quarter ended June 30, 2026. Resolute Holdings reported second quarter earnings per share attributable to common stockholders of $(1.53) compared to ($0.07) in the prior year and Non-GAAP Fee-Related Earnings per share of $0.69 compared to $0.08 in the prior year. The increase in Non-GAAP profitability was driven by the higher fee stream as a result of the execution of the management agreement with Husky Holdings LLC (“Husky Holdings”) in January 2026, along with organic growth in fees from the CompoSecure management agreement. During the second quarter and through the end of July, the company repurchased $50.0 million in common shares in open market purchases and has reduced its shares outstanding by approximately 8.3% since the spin-off.

BEDFORD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its second quarter ended June 30, 2026.

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Getty Copper Inc. (TSX-V: GTC; OTCQX: GTCDF), a Canadian-based mineral exploration and development company, has qualified to trade on the OTCQX® Best Market. Getty Copper Inc. upgraded to OTCQX from the Pink Limited™ Market.

Second Quarter HighlightsResults compared to prior year period unless otherwise noted; pro forma metrics inclusive of Husky.   

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions

Immunocore reports second quarter financial results and provides a business update

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 321,423 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holding to 4,793,684 common shares.

Record Quarterly Revenue of $50.2 Million, Up 52% Year-over-Year DSP Delivered Double-Digit Growth While Exchange Revenue Grew 108%Adjusted EBITDA Improved by $3.0 Million Year-over-Year to $2.0 Million

STILLWATER, Okla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (the Company), today announced that it will release financial results for the quarterly period ended June 30, 2026, after U.S. markets close on Monday, August 10, 2026. Additionally, the Company will host a conference call that afternoon to discuss the results and related matters.

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2026.

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating relevant patient-reported outcome (PRO) measures have been published in Frontiers in Immunology. The study findings directly informed the design of and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) investigating deucrictibant for the prophylaxis and on-demand treatment of AAE-C1INH attacks.

Delivered 6% Y/Y Net Sales Growth and $5.8M Adjusted EBITDA, Exceeding High End of Guidance RangeExpanded Gross Margin by 360 bps SequentiallyDrove 32% Y/Y Bookings Growth in Fine JewelryRaises Annual Profitability Guidance

(All dollar amounts are expressed in U.S. dollars, unless otherwise noted.)

GEORGE TOWN, Cayman Islands, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, released its monthly metrics for July 2026 on Thursday, August 6, 2026.

HOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- DNOW Inc. (NYSE: DNOW) announced results for the second quarter ended June 30, 2026.

Revenue of $731.1 million and Direct-to-Consumer (“DTC”) Revenue of $286.9 millionRevenue Decreased (1.8)% Sequentially and Increased 5.0% Year Over Year DTC Platforms Revenue Decreased (1.7)% Sequentially and Increased 63.1% Year Over Year

MAHIA, New Zealand, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB), a global leader in launch services and space systems, today successfully launched its 13th Electron rocket of the year to deploy the latest satellite to space for multi-launch customer Institute for Q-shu Pioneers of Space, Inc. (iQPS), operators of the QPS-SAR Earth-imaging constellation.

Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarterQ3 2026 expected revenue range of $65 to $80 million and adjusted EBITDA range of $7 to $15 millionEuropean Thermal Barrier 2026 revenue outlook raised to $20 to $30 millionPyroThin® award from Jaguar Land Rover for two next-generation vehicle architectures

Increase technology powers an API-first banking platform for ACH, check, and virtual card payments within VicPay, connecting the AP lifecycle from invoice ingestion through payment execution and reconciliation

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter ended June 30, 2026.